TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25906565
Drug: Triple-strong stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-strong stimulation therapy group
Study: 25906565
Drug: Acupoint plaster
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint plaster therapy group
Study: 19784467
Drug: InGaAlP laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: InGaAlP laser (660 nm) and GaAlAs laser (780 nm), 25 mW potency, 6.3J/cm(2) dose, 10‐s irradiation time, followed by conventional treatment (Mucositis Formula)
Study: 19784467
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (Mucositis Formula) only
Study: 15116086
Drug: Both dietary
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both dietary treatments
Study: 14649615
Drug: 4-minute, 1.23%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-minute, 1.23% APF gel treatment
Study: 14649615
Drug: AL irradiation
Normalized name: AL-034
DrugBank: AL-034 (DB17471)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AL irradiation followed by APF gel treatment
Study: 6700643
Drug: Dexamethasone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (4 mg every 6 hours for 48 hours)
Study: 30327362
Drug: Insulin Pump
Normalized name: insulin pump syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin Pump
Study: 2336873
Drug: Immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy with a vaccine consisting of autoclaved Mycobacterium w
Study: 2336873
Drug: Chemotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and placebo injections
Study: 377219
Drug: Weekly immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly immunotherapy combining BCG and irradiated leukaemic cells
Study: 377219
Drug: Monthly reinduction
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly reinduction chemotherapy
Study: 25744500
Drug: Accelerated high-frequency
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Accelerated high-frequency (HF) rTMS treatment
Study: 19447570
Drug: Sustained-release (SR)
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release (SR) bupropion plus transdermal nicotine patch
Study: 9270638
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy (cisplatin and 5-fluorouracil)
Study: 9270638
Drug: Surgical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical therapy alone
Study: 27852098
Drug: Water plus
Normalized name: Premium Gripe Water Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water plus 100 mg simethicone (group B)
Study: 27852098
Drug: Water plus
Normalized name: Premium Gripe Water Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water plus 100 mg simethicone plus 600 mg N-acetylcysteine (group C)
Study: 24018711
Drug: Tamsulosin (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin (0.4 mg o.d.) and ketoconazole (200 mg t.d.s.)
Study: 24018711
Drug: Tamsulosin (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin (0.4 mg o.d.) and placebo
Study: 21233029
Drug: Budesonide 64
Normalized name: budesonide 64 MCG/ACTUAT Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 64 μg/dose nasal spray
Study: 21233029
Drug: Budecort Aqua®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budecort Aqua® 64 μg/dose nasal spray
Study: 18653484
Drug: Licofelone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licofelone (200 mg twice a day)
Study: 14700144
Drug: 10 per
Normalized name: 10 Person ANSI KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 per cent sulfur ointment
Study: 14700144
Drug: 0.3 per
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 per cent gamma benzene hexachloride gel
Study: 25359382
Drug: COBRA Classic
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: COBRA Classic (methotrexate (MTX)+ sulfasalazine+60 mg prednisone tapered to 7.5 mg daily from W7)
Study: 25359382
Drug: COBRA Slim
Normalized name: benzalkonium chloride Topical Foam [DigiClean Slim-Line]
Approvals — FDA: no, EMA: no, PMDA: no
Description: COBRA Slim (MTX+30 mg prednisone tapered to 5 mg from W6)
Study: 25359382
Drug: COBRA Avant-Garde
Normalized name: Eco-Gard
Approvals — FDA: no, EMA: no, PMDA: no
Description: COBRA Avant-Garde (MTX+leflunomide+30 mg prednisone tapered to 5 mg from W6)
Study: 8104978
Drug: Twice-daily skin
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily skin preparation with 10% aqueous povidone-iodine for 48 h preoperatively (Group A, N = 34)
Study: 8104978
Drug: No skin
Normalized name: Aveeno Skin Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: No skin preparation (Group B, N = 30)
Study: 3516177
Drug: Ampicillin sodium/amoxicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin sodium/amoxicillin trihydrate therapy
Study: 31054010
Drug: Probiotic (Symprove™,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic (Symprove™, 1 ml/kg/day for 4 weeks)
Study: 18207598
Drug: Low-dose daily
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose daily cisplatin
Study: 18207598
Drug: Hyperfractionated radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperfractionated radiotherapy (77Gy in 70 fractions in 35 treatment days)
Study: 9171065
Drug: Methylprednisolone (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (80 mg in 8 ml of isotonic saline)
Study: 9171065
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline (1 ml)
Study: 31959707
Drug: Direct Oral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct Oral Anticoagulants (DOA)
Study: 23774797
Drug: LDA 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDA 100 mg (regimen A)
Study: 23774797
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg (regimen C)
Study: 23774797
Drug: LDA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDA with rabeprazole 10 mg (regimen AC)
Study: 16571279
Drug: Taizhi'an capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taizhi'an capsule (TZA) 0.9 g 3 times a day + Simvastatin (Sim) 10 mg at bedtime
Study: 16571279
Drug: Simvastatin (Sim)
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin (Sim) 20 mg at bedtime
Study: 7750187
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated oestrogens (OCE, 0.625 mg) + Medroxyprogesterone acetate (MPA, 5 mg)
Study: 7750187
Drug: Transdermal oestradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal oestradiol (TE, 50 micrograms) + Medroxyprogesterone acetate (MPA, 5 mg)
Study: 2212918
Drug: Metronidazole 1
Normalized name: metronidazole 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 1 g daily for 7 days
Study: 7067925
Drug: Tinidazole 2
Normalized name: tinidazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinidazole 2 g single dose
Study: 31769240
Drug: Insulin Degludec/Insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin Degludec/Insulin Aspart (IDegAsp)
Study: 27756182
Drug: Theaflavin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theaflavin (50 or 100 mg/day)
Study: 27756182
Drug: Catechin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Catechin (400 mg/ml)
Study: 16638862
Drug: Concurrent high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent high-dose IL-2
Study: 16638862
Drug: Recombinant vaccinia
Normalized name: Dna (recombinant vaccinia virus strain livp clone gl-onc1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant vaccinia and fowlpox vaccines
Study: 16638862
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment with IL-2
Study: 8508692
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg oral ciprofloxacin administered 1, 2 or 3 hours before anesthesia
Study: 8508692
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg gentamicin plus 500 mg metronidazole administered intravenously
Study: 22285278
Drug: SQ-standardized grass
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQ-standardized grass allergy immunotherapy tablet (Grazax)
Study: 18712620
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release (SR) tablets of dextromethorphan hydrobromide
Study: 18712620
Drug: Immediate release
Normalized name: Namenda, immediate release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release tablets of dextromethorphan hydrobromide
Study: 15968890
Drug: CO2 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CO2 treatment for 18 days
Study: 1351600
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese herbal therapy (TCHT)
Study: 3880780
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of terodiline and meladrazine
Study: 30634203
Drug: Shenkang Injection
Normalized name: CAMPHOR (SYNTHETIC) 4.28 mg in 100 mg / MENTHOL 2.84 mg in 100 mg / METHYL SALICYLATE 1.4 mg in 100 mg TRANSDERMAL PLASTER [Shennong Analgesic Plaster]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenkang Injection (SI)
Study: 30634203
Drug: Rehydration therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rehydration therapy (normal saline)
Study: 30634203
Drug: 5% glucose
Normalized name: Dextrose/Water 5% Oral Solution [ENFAMIL 5% GLUCOSE IN WATER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% glucose injection (control)
Study: 20158295
Drug: Negative affect
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative affect cue (speech preparation task)
Study: 12182909
Drug: front-loaded rt-PA
Normalized name: rt-PA
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: front-loaded rt-PA (up to 100 mg)
Study: 12182909
Drug: TNK-tPA (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNK-tPA (single bolus up to 50 mg)
Study: 10469772
Drug: Dexamethasone (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.25 mg/kg on days 1-7, 0.12 mg/kg on days 8-14, 0.05 mg/kg on days 15-21, 0.02 mg/kg on days 21-28)
Study: 1725549
Drug: Calcium blockers
Normalized name: CALCIUM CHANNEL BLOCKERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium blockers (diltiazem)
Study: 1725549
Drug: Calcium antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium antagonists (dihydropiridines)
Study: 1725549
Drug: Calcium blockers
Normalized name: CALCIUM CHANNEL BLOCKERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium blockers and ACE inhibitors
Study: 366143
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg levamisole once weekly
Study: 6218948
Drug: 350 mg
Normalized name: hemin 350 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 350 mg daily doses of levamisole for 3 consecutive days weekly
Study: 17906163
Drug: Tadalafil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil (5 mg/d) with doxazosin (1, 2, and 4 mg/d)
Study: 17906163
Drug: Tadalafil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil (5 mg/d) with tamsulosin (0.4 mg/d)
Study: 17906163
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with doxazosin (4 mg/d)
Study: 17906163
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with tamsulosin (0.4 mg/d)
Study: 17906163
Drug: Doxazosin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (4 mg/d) with placebo
Study: 9451062
Drug: 7.2% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.2% saline solution
Study: 7658056
Drug: Aerosolized pentamidine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized pentamidine, 300 mg every month
Study: 7658056
Drug: Dapsone, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapsone, 50 mg/day
Study: 2684251
Drug: Extradural clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extradural clonidine (EC) 2 micrograms kg‐1 in isotonic saline solution 15 micrograms ml‐1
Study: 2684251
Drug: Extradural saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extradural saline (ES) equivalent volume of plain isotonic saline solution
Study: 24135389
Drug: Metformin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin + Rosiglitazone
Study: 29654849
Drug: Insulin regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin regimens (short or long-acting)
Study: 23426461
Drug: teduglutide (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: teduglutide (0.5 mg/kg/d)
Study: 23426461
Drug: teduglutide (0.10
Approvals — FDA: no, EMA: no, PMDA: no
Description: teduglutide (0.10 mg/kg/d)
Study: 10892359
Drug: Invasive surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Invasive surgical treatments for acute myocardial infarction
Study: 9001926
Drug: Metered Dose
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metered Dose Inhaler (MDI) - nedocromil sodium 4 mg + salbutamol 0.2 mg
Study: 9001926
Drug: Nebulizer Solution
Normalized name: Intal 20mg/2ml Nebulizer Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulizer Solution - nedocromil sodium 10 mg + salbutamol 1.5 mg
Study: 9001926
Drug: Nebulizer Solution
Normalized name: Intal 20mg/2ml Nebulizer Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulizer Solution
Study: 6424240
Drug: Daily topical
Normalized name: Clindagel 1 % Once-Daily Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily topical applications of povidone‐iodine
Study: 29273946
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU), standard referral to treatment
Study: 26221051
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (sham)
Study: 23185756
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal enema therapy (CHET), once daily for 2 weeks as one therapeutic course
Study: 23185756
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal enema therapy (CHET)
Study: 23185756
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal enema therapy (CHET) and basic treatment
Study: 20397286
Drug: Bupropion XL
Normalized name: Bupropion Hydrochloride 150 MG Oral Tablet, Extended Release [BUPROPION XL]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion XL 300 mg
Study: 16335686
Drug: Insulin treatment
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin treatment (subgroup AII)
Study: 16335686
Drug: Sulfonylurea treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfonylurea treatment (subgroup AI)
Study: 2403227
Drug: 0.1 mL
Normalized name: ethanol 0.1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mL influenza vaccine
Study: 2403227
Drug: 0.05 mL
Normalized name: xenon 0.05 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mL influenza vaccine
Study: 2403227
Drug: 0.5 mL
Normalized name: ethanol 0.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mL influenza vaccine
Study: 2403227
Drug: 0.1 mL
Normalized name: ethanol 0.1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mL and 0.05 mL influenza vaccine
Study: 630187
Drug: ioglycamide (Biligram)
Normalized name: ioglycamic acid
DrugBank: Ioglycamic acid (DB13741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ioglycamide (Biligram) at 3 mg/kg/min for one hour
Study: 630187
Drug: ioglycamide (Biligram)
Normalized name: ioglycamic acid
DrugBank: Ioglycamic acid (DB13741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ioglycamide (Biligram) at 4 mg/kg/min for one hour
Study: 630187
Drug: ioglycamide (Biligram)
Normalized name: ioglycamic acid
DrugBank: Ioglycamic acid (DB13741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ioglycamide (Biligram) at 2 mg/kg/min drip infusion
Study: 630187
Drug: ioglycamide (Biligram)
Normalized name: ioglycamic acid
DrugBank: Ioglycamic acid (DB13741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ioglycamide (Biligram) by 10 minute slow hand injection
Study: 21460356
Drug: Oxabact (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxabact (oral administration)
Study: 18087163
Drug: Omalizumab at
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Omalizumab at a dose of >=0.016 mg/kg/IgE every 4 weeks
Study: 16291387
Drug: PCEA (ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCEA (ropivacaine 3.2 mg + fentanyl 8 microg/dose)
Study: 16291387
Drug: IV-PCA (morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV-PCA (morphine 2 mg/dose)
Study: 10460982
Drug: 14‐day training
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14‐day training of a relaxation therapy including a 30‐minute lullaby‐like, rhythmically dominated music with gradually decreasing tempi
Study: 8529732
Drug: Oral diclofenac
Normalized name: diclofenac Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diclofenac 50 mg 3 times a day for 7 days
Study: 619075
Drug: HPV‐77 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV‐77 vaccine
Study: 619075
Drug: RA‐27/3 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RA‐27/3 vaccine (subcutaneously)
Study: 619075
Drug: RA‐27/3 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RA‐27/3 vaccine (intranasally)
Study: 619075
Drug: RA‐27/3 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RA‐27/3 vaccine
Study: 23928094
Drug: BIIB023 (0.03-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIIB023 (0.03-20 mg/kg)
Study: 11573658
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion at 2 microg ml(‐1) with two word lists (category examples and nonsense words)
Study: 11573658
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion at 5 microg ml(‐1) with nonsense words before tracheal intubation and category examples during intubation
Study: 11573658
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion at 5 microg ml(‐1) with category examples before and nonsense words during intubation
Study: 9591926
Drug: 40 microg
Normalized name: Travoprost 40 microgram/mL eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 microg from a metered‐dose inhaler plus spacer
Study: 7846921
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg b.i.d. with preoperative cathartic (group OA, n = 159)
Study: 7846921
Drug: No oral
Normalized name: Beano Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No oral antibiotic (group NOA, n = 168)
Study: 20924294
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural infusion morphine
Study: 20924294
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural infusion morphine with Bupivacaine
Study: 31571329
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy (PT) programme (12 sessions)
Study: 16051499
Drug: Threshold therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Threshold therapy with 30% load
Study: 11518831
Drug: GH dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH dosage group A, 4 IU/m(2)/d
Study: 11518831
Drug: GH dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH dosage group B, first year 4 IU/m(2)/d, thereafter 6 IU/m(2)/d
Study: 11518831
Drug: GH dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH dosage group C, first year 4 IU/m(2)/d, second year 6 IU/m(2)/d, thereafter 8 IU/m(2)/d
Study: 9625091
Drug: Olestra (20-35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olestra (20-35 g)
Study: 7933659
Drug: 1800 mg
Normalized name: glycerin 1800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1800 mg IPA-E
Study: 7933659
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg IPA-E
Study: 7933659
Drug: Control (pre-administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (pre-administration values)
Study: 2463717
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg metoprolol per day
Study: 2661389
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg metoprolol per day
Study: 30141180
Drug: Cinacalcet (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinacalcet (0.25 mg/kg)
Study: 28346377
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of UCA and randomized beamforming scheme
Study: 15567053
Drug: TFL-assisted treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TFL-assisted treatment group